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DNA-based immunization represents a novel approach
for vaccine development. Recombinant DNA techniques
are used to clone DNA sequences encoding antigens of
choice into eukaryotic expression plasmids, which are
readily and economically amplified in bacteria and
recovered with a high degree of purity. For immuniza-
tion, plasmid DNA is either coated onto microscopic
gold particles and bombarded into skin using a gene gun
or injected into skin or muscle. Expression of adminis-
tered genes results in the induction of humoral and
cellular immune responses against the encoded antigen.
DNA immunization is capable of inducing protective
immunity in a number of animal models of infectious
disease and cancer. Recent studies suggest that antigen-
specific cytotoxic T lymphocyte induction occurs
through the presentation of appropriate peptides in the
context of major histocompatibility complex molecules
SIMPLE INJECTIONS OF PLASMID DNA INTO THE SKIN
ELICIT EFFECTIVE HUMORAL AND CELL-MEDIATED
IMMUNITY
Various gene transfer techniques have been investigated by gene
therapists to efficiently express recombinant proteins in the epidermis
for the systemic delivery of growth factors or hormones. One approach
uses purified plasmid DNA coated onto microscopic gold particles
(1–3 µm in size) that are accelerated into target cells or tissues by
physical means with a ‘‘gene gun’’ (Klein et al, 1987; Yang et al, 1990;
Williams et al, 1991). Transient in vivo expression of reporter genes
such as β-galactosidase or firefly luciferase can readily be demonstrated
in rodents following such particle bombardment of the skin. In 1992,
Johnston and colleagues reported the surprising observation that
particle-mediated gene transfer of an expression plasmid encoding
human growth hormone into the skin of mice resulted not only in
the systemic delivery of the molecule but also in the induction of
antigen-specific antibody responses (Tang et al, 1992). Subsequently,
several groups have demonstrated that immunizations with purified
plasmid DNA encoding influenza antigens using simple intramuscular
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on bone marrow-derived professional antigen presenting
cells. Following DNA inoculation into the skin, Langer-
hans cells and/or dermal dendritic cells are believed to
acquire the newly synthesized antigen, either through
direct transfection or via antigen uptake from transfected
keratinocytes, and migrate to regional lymph nodes where
they stimulate primary T cell responses. The nature of
the immune response depends on the route, method, and
timing of DNA delivery and can also be influenced by
co-delivery of plasmids encoding immunomodulating
cytokines like IFN-a, IL-2, or IL-12 and costimulatory
molecules like B7–1. While many aspects of the biology
of cutaneous DNA immunization remain unknown, the
skin appears to offer unique potential as a target for
DNA-based immunization. Key words: dendritic cells/gene
gun/Langerhans cells/nucleic acid vaccine. J Invest Dermatol
111:183–188, 1998
injections or particle bombardment of the skin protected mice against
a lethal challenge with live influenza virus (Fynan et al, 1993; Ulmer
et al, 1993; Wang et al, 1993; Robinson et al, 1993; Davis et al, 1993).
It is now well established that immunization with plasmid DNA
delivered either by cutaneous particle bombardment or by intradermal
or intramuscular needle-injection activates both humoral and cellular
immune responses, including the generation of antibody responses
specific for conformational determinants, as well as antigen-specific
CD81 cytotoxic T cells and CD41 T helper cells. Importantly, antigen-
specific antibodies and cytotoxic T lymphocyte (CTL) reactivity could
be detected in rodents for more than 1 y (Pardoll and Beckerleg,
1995), suggesting that plasmid DNA immunization may promote long-
lasting humoral and cellular immune responses qualitatively similar to
live attenuated or recombinant viral vaccines without the hazards of
pathogenicity. These results have provided the basis for an entirely
new and rapidly expanding field of vaccine development.
Plasmids employed for DNA immunizations generally contain an
origin of replication and an antibiotic resistance gene suitable for
propagation in Escherichia coli. The gene of interest is typically under
the transcriptional control of a viral promoter followed by a mRNA
termination/polyadenylation sequence allowing for strong expression
in mammalian cells (Fig 1). Vaccines consisting of naked plasmid DNA
have several important advantages over alternate approaches such as
purified or recombinant proteins and live attenuated or recombinant
viruses. They can easily be constructed for any suitable antigen and
produced economically in large quantities with a high degree of purity
and stability. Furthermore, they offer the promise of a molecularly
defined reagent that allows for antigen synthesis in vivo with native
post-translational modifications and protein conformation, but are not
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Figure 1. Schematic diagram of plasmid DNA typically used for DNA
immunization. The origin of replication (here from the bacteriophage f1)
and an antibiotic resistance gene (here ampicillin) in the plasmid backbone
allow for expansion of the plasmid in E. coli. A promoter/enhancer (here a
CMV promoter) followed by an intron initiates transcription of the gene of
interest (here the melanoma-associated antigen TRP-2) that is terminated by a
polyadenylation signal (here SV40 poly A).
infectious and are incapable of replication. Plasmid DNA can be
delivered in a very simple fashion either by particle bombardment of
the skin or by intradermal or intramuscular needle injection. An
increasing number of studies have demonstrated that immunizations
with plasmid DNA promote effective immune responses against many
viruses, bacteria, and parasites in rodents (reviewed by Donnelly et al,
1997). More importantly, DNA immunization has also shown efficacy
in primates (Davis et al, 1996; Boyer et al, 1996) and inoculations of
cDNA expression vectors for HIV gp160 and gag/pol have been found
to protect chimpanzees from high dose heterologous HIV-1 challenge
(Boyer et al, 1997). Human clinical evaluations have recently been
initiated for several infectious diseases including HIV, HBV, and
influenza virus. With the molecular identification of tumor antigens
(Boon and Van der Bruggen, 1996), there has also been increasing
interest in the development of DNA immunization for tumor immuno-
therapy. DNA immunization of mice targeting model tumor antigens
such as chicken ovalbumin (Condon et al, 1996), β-galactosidase (Irvine
et al, 1996), and carcinoembryonic antigen (Conry et al, 1996), as well
as idiotypic determinants of the immunoglobulin expressed on the
surface of B cell lymphomas (Syrengelas et al, 1996) or the tumor-
specific antigen P815 (Rosato et al, 1997), induced protective immune
responses leading to rejection of a subsequent, normally lethal challenge
with tumor cells expressing the respective antigen.
PROFESSIONAL ANTIGEN PRESENTING CELLS (APC)
PLAY A CENTRAL ROLE IN THE INDUCTION OF
CELL-MEDIATED IMMUNITY
The precise cellular and molecular events leading to the induction of
immune responses following inoculation of plasmid DNA are not
fully understood. Important aspects of the biology of cell-mediated
immunity, including the mechanisms of antigen processing and
presentation and the requirements for the induction of primary T cell
responses, have been resolved in the past decade (Fig 2). We now
know that CD81 cytolytic T lymphocytes, the predominant effector
cells for many viral diseases and certain tumors, recognize 8–12
amino acid long peptides in association with major histocompatibility
complex (MHC) class I molecules. MHC class I-presented peptides
generally derive from endogenously synthesized protein antigens, which
are processed in the cytosol by the multicatalytic proteasomes. Such
peptides are delivered into the endoplasmic reticulum by a transporter
associated with antigen presentation (TAP), where they bind to nascent
MHC class I heavy chains and β2-microglobulin and are subsequently
transported to the cell surface. As an exception to this rule, however,
certain phagocytic cell types such as macrophages or dendritic cells
(DC) have been found to also take up exogenous proteins for class
I-restricted presentation (York and Rock, 1996). CD41 helper T
lymphocytes, in contrast, recognize 12–25 amino acid long peptides
in association with MHC class II molecules. These MHC class II-
presented peptides predominantly derive from exogenous antigens,
which are taken up into endocytic compartments and are degraded by
endosomal and lysosomal proteases before binding to newly synthesized
or recycled MHC class II molecules (Cresswell, 1994; Watts, 1997).
Studies investigating the requirements for the induction of primary
antigen-specific T cell responses have shown that full T cell activation
and expansion requires antigen presentation by professional APC such
as B cells, macrophages, or DC. These APC are capable of presenting
the antigen to T cells in the context of additional immunostimulatory
signals provided by costimulatory molecules like B7.1 (CD80), B7.2
(CD86), and CD40 on their surface, which bind to CD28 and CD40 L
(CD154) on T cells, respectively (Lenschow et al, 1996; Grewal and
Flavell, 1996). T cell recognition of antigen presented by professional
APC initiates a molecular dialogue leading to the further upregulation
of costimulatory molecules and the production of immunostimulatory
cytokines like IL-1 and IL-12 by DC and IFN-γ by T cells, a process
that has been termed T cell-mediated terminal maturation of DC
(Kitajima et al, 1996; Koch et al, 1996). T cells appear to integrate
intracellular signals received through serially triggered T cell receptors
with signals received from receptors for costimulatory molecules like
CD28 and CD40 L and from receptors for T cell growth factors like
IL-2, IL-7, or IL-12, and can respond with anergy, partial, or full
activation (Lanzavecchia, 1997). Activation of T cells is inhibited by
signals received from CTLA-4 (Chambers and Allison, 1997), whereas
proliferation also appears to be regulated by the induction of apoptosis
(Lu et al, 1997).
Several recent investigations have shown that professional APC play
a central role for the stimulation of cellular immunity following DNA
immunization. Initially the induction of strong CTL responses was
believed to be a consequence of the intracellular antigen synthesis in
target cells in vivo following DNA immunization. The predominant
transfected cell types following intradermal or intramuscular inocula-
tions of DNA, however, are keratinocytes and myocytes. Presentation
of MHC-bound peptide antigens to T cells by keratinocytes or
myocytes that lack expression of costimulatory molecules such as B7.1
and B7.2 would be expected to result in immunologic ignorance (due
to the low levels of MHC determinants) or tolerance (due to lack of
costimulatory signals). To address the role of APC for the induction
of CD81 CTL responses following DNA immunization, studies were
performed with bone marrow-chimeric mice (Corr et al, 1996; Doe
et al, 1996; Fu et al, 1997; Iwasaki et al, 1997b). In a representative
experiment, the influenza nucleoprotein was utilized as a model antigen,
because nucleoprotein-derived CTL epitopes have been defined for
multiple strains (H-2b, H-2d, and H-2k). Parent →F1 bone marrow
chimeras were generated in which H-2b3d (C57BL/6 3 BALB/C)
recipient mice received bone marrow that expressed only H-2b
(C57BL/6) or H-2d (BALB/C) MHC molecules. As H-2b or H-2d T
cells are educated in an H-2b3d thymus, these CTL are capable of
recognizing peptide antigens presented by both H-2b and H-2d (Fu
et al, 1997); however, CTL responses following immunization with
plasmid DNA encoding influenza nucleoprotein via intramuscular or
intradermal inoculations were restricted to the MHC haplotype of the
bone marrow alone and not to the second haplotype expressed by the
recipient’s myocytes (Fig 3). Thus, CTL could only be stimulated if
the appropriate peptides were presented in the context of MHC
molecules on bone marrow-derived professional APC, ruling out the
possibility that keratinocytes or myocytes would directly activate
cytotoxic T cells. This view was further supported by another experi-
ment, where nucleoprotein-transfected myoblasts (H-2k) were trans-
planted into F1 bone marrow chimeras in which H-2k3d (C3H 3 DBA/
2) recipient mice received bone marrow that expressed only H-2d
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Figure 2. Mechanisms of antigen pro-
cessing and presentation and requirements
for the induction of primary T cell
responses. Antigens are recognized by T cell
receptors in the form of short peptides associated
with MHC molecules on the cell surface. CD81
T cells recognize peptides bound to MHC class I
that generally derive from intracellular antigens,
whereas CD41 T cells recognize peptides
bound to MHC class II molecules that are
generally derived from extracellular antigens.
Full activation of T cells requires TCR engage-
ment and additional costimulatory signals that
are provided by professional APC.
Figure 3. Bone marrow-derived profes-
sional APC are required for the stimulation
of primary CTL responses following DNA
immunization. Experiments with bone
marrow-chimeric mice demonstrate that CTL
elicited by DNA immunization are restricted
to the MHC haplotype of the bone marrow
alone, ruling out the possibility that transfected
keratinocytes directly stimulate primary CTL
responses (Iwasaki et al, 1997b; Fu et al, 1997).
(DBA/2) MHC molecules (Ulmer et al, 1996). Here the resulting
influenza nucleoprotein-specific CTL was again restricted by the
haplotype of the bone marrow (H-2d). Thus, specific CTL responses
could only be induced as a result of the transfer of antigen from the
transplanted muscle cells (H-2k) to a genetically disparate bone marrow-
derived APC (H-2d) capable of processing and presenting extracellular
proteins via the MHC class I pathway (cross-priming). These studies
demonstrate that the initiation of cell-mediated immune responses
following plasmid DNA immunization requires that bone marrow-
derived APC present immunogenic peptides derived from the encoded
antigen to naı¨ve T cells.
THE SKIN AS AN IDEAL TARGET FOR DNA
IMMUNIZATION
Given the critical role for APC in the induction of cellular immune
responses to plasmid-encoded antigens, the skin appears to be an
ideal target for DNA immunization. Skin contains numerous, readily
accessible bone marrow-derived Langerhans cells and dermal DC,
which are specialized for the initiation of immune responses. In the
model we propose, subsequent to DNA inoculation into the skin,
Langerhans cells and/or dermal DC could acquire antigen either
through direct transfection, or through uptake and presentation of
antigen synthesized in transfected keratinocytes or other skin cells, or
both (Fig 4). In addition, unique immunologic features of the cutaneous
microenvironment, including contributions from nonmigratory cells,
could influence the nature and overall magnitude of the resulting
immune response. Both keratinocytes and Langerhans cells/DC are
able to secrete proinflammatory cytokines such as IL-1, TNF-α, and
GM-CSF in response to allergens, infection, or injury (Luger et al,
1996). These cytokines can promote Langerhans cell maturation and
migration to regional lymph nodes where antigenic peptides are
presented to naı¨ve T cells (Steinman, 1991; Cella et al, 1997). Secretion
of such immunomodulatory factors in response to DNA delivery or
foreign DNA itself (see below) could have significant qualitative and
quantitative effects on the immune response generated from cutaneous
gene delivery.
We have demonstrated that cutaneous DNA immunization using
the gene gun can result in the direct transfection of skin-derived DC
in vivo, which localize in the T cell rich areas of draining lymph nodes
(Condon et al, 1996). Consistent with these observations, it was
recently demonstrated that DC migrating out of DNA-injected tissue
were associated with antigen in an immunogenic form and could
stimulate immune responses against the transgene encoded antigen
(Casares et al, 1997). In addition, several studies demonstrate that
cultured DC or DC lines, transfected in vitro with antigen encoding
genes, can elicit potent antigen-specific responses in vivo following
adoptive transfer (Manickan et al, 1997; Timares-Lebow et al, 1997;
Tu¨ting et al, 1997). In the context of previous studies demonstrating
the remarkable in vivo immunogenicity of very low numbers of
Langerhans cells (McKinney and Streilein, 1989), these studies support
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Figure 4. The role of skin-derived DC in
the induction of cell-mediated immune
responses following cutaneous DNA
immunization. Langerhans cells are either
directly transfected or acquire antigen from
transfected keratinocytes. Injury and the
presence of immunostimulatory sequences in
bacterial DNA elicit the production of pro-
inflammatory cytokines by keratinocytes and
initiate migration and maturation of antigen-
bearing Langerhans cells. Primary T cell
responses are stimulated in the T cell rich areas
of regional lymph nodes.
the importance of DC for DNA-based immunization, and suggest that
the direct transfection of relatively few Langerhans cells may be
sufficient to account for the induction of potent immune responses.
Recently published studies suggest that for cutaneous DNA
immunization, the integrity of targeted skin may influence the nature
of the immune response, and may be critical for optimal immuno-
genicity. In a series of experiments, Torres et al have compared the
influence of skin with muscle target tissues on the nature of the
immune response (Torres et al, 1997). These studies suggest that
excision of targeted skin within 24 h after gene gun bombardment can
significantly inhibit antibody or CTL responses in some mice. In
contrast, excision of needle-injected muscle bundles as early as 10 min
after injection had minimal effects on the induction of antibody or
CTL responses. Whether the observed differences in target tissue
dependency in these studies are a result of unique immunologic features
of skin versus muscle, or a result of the method of DNA delivery
(biolistic bombardment of skin versus needle injection of muscle), is
unclear. These observations do suggest that the integrity of the target
skin is required for optimal immunogenicity after biolistic gene delivery.
In studies focusing on skin, Klinman et al have recently addressed this
same issue, but with a more detailed kinetic analysis (Klinman et al,
1998). Significantly, their studies also included a complementary
assessment of the immunogenicity of skin excised from the immuniza-
tion site and grafted onto naive littermates. Their studies show that
when the vaccination site is left in place for as little as 5 h, both
primary and secondary antibody responses, as well as memory T cell
responses, could be generated. By 24 h, primary T cell responses
were observed as well. All responses reached maximum levels when
immunized skin was left intact for 3–7 d. Importantly, transfer of
immunized skin to naive recipients could induce immune responses if
the skin was transferred within 5–12 h of immunization, but was
ineffective in inducing immunity if transferred later.
Together, these results suggest that immunity is induced by cells that
migrate rapidly from the site of immunization. Previous studies have
demonstrated DC influx into draining lymph nodes as soon as 4 h
after hapten painting of skin and peaking 2 d after exposure before
gradually declining (Macatonia et al, 1986, 1987), suggesting that
continued skin integrity could facilitate continuing accumulation of
Langerhans cells from the target site in the draining lymph nodes
during this time period. The possibility that nonmigratory cells in
intact target skin could contribute to the immune response by secretion
of proinflammatory cytokines that effect Langerhans cells maturation
and migration, and/or by the eventual synthesis and release of antigen
by keratinocytes or other skin cells that can be taken up and re-
presented by professional APC or recognized by B cells, is also consistent
with these results. The observation that transfer of immunogenicity to
skin-graft recipients can only take place if the target skin is excised
and grafted within the first 12 h after gene delivery, could be interpreted
as evidence that directly transfected migrating DC are critical for
immunogenicity. Alternative interpretations, however, including the
possibility that antigens produced in nonmigratory cells are taken up
by resident DC before migration, are also feasible.
Clearly, further investigations will be necessary to fully understand
the events leading to the induction of immune responses following
cutaneous gene delivery, including the relative contributions of direct
presentation of endogenously synthesized antigen by transfected APC
versus their re-presentation of antigens synthesized by other cell types.
In any case, the finding that Langerhans cells can be transfected in vivo
raises the exciting possibility that these migrating professional APC can
be genetically engineered in vivo (Condon et al, 1996). By designing
strategies to co-deliver genes encoding antigens with genes encoding
immunoregulatory molecules to the same APC, it should be possible
to either induce or suppress antigen-specific immune responses in the
host. Such in vivo genetic engineering strategies could have a significant
clinical impact not only for vaccine design, but for transplantation and
the treatment of autoimmune diseases as well.
IMMUNE RESPONSES ARE INFLUENCED BY THE
NATURE OF BACTERIAL PLASMID DNA
It has recently been appreciated that the method of DNA delivery
influences the type of immune response. Intradermal or intramuscular
injections of plasmid DNA in saline appear to preferentially induce T
helper 1-like (Th1) immune response in mice, with the expansion of
IFN-γ-producing CD41 T cells and CD81 CTL. This is associated
with the predominant production of antibodies of the IgG2a isotype
and very low titers of antibodies of the IgE isotype (Raz et al, 1996;
Pertmer et al, 1996; Feltquate et al, 1997). In contrast, plasmid DNA
immunization using the gene gun targeting skin (Pertmer et al, 1996)
or muscle (Feltquate et al, 1997) appears to induce immune responses
with a T helper 2-like (Th2) phenotype, characterized by IL-4-
producing CD41 T cells and the predominant production of antibodies
of the IgG1 isotype.
These surprising results may reflect the different gene transfer
methodologies. DNA must be taken up by cells from extracellular
spaces following injection in saline. In contrast, particle bombardment
directly results in intracellular DNA delivery. Efficient transfection and
reproducible induction of immune responses by needle injection
generally requires 25–100 µg of DNA, whereas nanogram quantities
of DNA were found to be effective when using the gene gun (Pertmer
et al, 1996). In addition, the finding that immunostimulatory DNA
sequences (ISS) containing unmethylated CpG dinucleotide motifs
present in bacterial plasmid DNA are required for effective induction
of immune responses following immunization with plasmid DNA,
may provide a possible explanation for the promotion of such divergent
T helper cell phenotypes. Using β-galactosidase as a model antigen, it
could be shown that the Th1 bias of the immune response induced
by intradermal inoculation of plasmid DNA in saline was maximal
when the plasmid DNA backbone contained such ISS (Sato et al,
1996). Concomitant injection of ISS-deficient plasmid DNA encoding
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the antigen with noncoding ISS-enriched plasmid DNA also favors a
Th1 response, indicating that the ISS-enriched plasmid DNA exerts
an adjuvant effect. This adjuvant effect appeared to be mediated by
the local production of the Th1-biasing cytokines. Using polymerase
chain reaction techniques, it was demonstrated that the injection of
ISS-rich plasmids DNA induced the expression of IFN-α/β and IL-12
in the skin. Both the type I interferons and IL-12 are known to
enhance the generation and increase the cytotoxicity of natural killer
cells and CD81 CTL and to promote a T helper 1-like phenotype
(characterized by high IFN-γ production) in the antigen-specific
differentiation of naı¨ve CD41 T cells (Trinchieri, 1995; Belardelli and
Gresser, 1996). Several groups have reported that bacterial DNA
containing ISS is capable of activating macrophages and natural killer
cells in vitro, leading to the production of IFN-α/β, IFN-γ, TNF-α,
IL-1, IL-6, IL-12, and IL-18 (Ballas et al, 1996; Klinman et al, 1996,
1997; Stacey et al, 1996; Roman et al, 1997). Thus, injection of high
doses of ISS-containing plasmid DNA can activate innate immunity
through the local production of Th1-biasing cytokines within the skin
or muscle and can significantly promote the induction of antigen-
specific cell-mediated immunity (Roman et al, 1997; Carson and Raz,
1997; Chu et al, 1997). In contrast, gene gun immunizations into the
skin, which use only one-hundredth as much plasmid DNA compared
with saline DNA immunizations, may be less affected by the adjuvant
properties of ISS-containing bacterial DNA leading to immune
responses with a Th2 bias.
CELLULAR AND HUMORAL IMMUNE RESPONSES CAN
BE MANIPULATED AT THE MOLECULAR LEVEL
The nature of the immune response elicited by plasmid DNA
immunization can be manipulated through the adjuvant delivery of
genes encoding appropriate immunomodulating cytokines or
costimulatory molecules. Adjuvant administration of plasmids
encoding factors influencing the growth, differentiation, and matura-
tion of APC such as GM-CSF (Xiang and Ertl, 1995, Conry et al,
1996), T cell growth factors such as IL-2 and IL-7 (Chow et al, 1997;
Geissler et al, 1997), and Th1-biasing cytokines such as IFN-α and IL-
12, can selectively enhance the induction of cell-mediated immunity
in mice (Tsuji et al, 1997; Iwasaki et al, 1997a; Kim et al, 1997a). We
found that epidermal gene gun immunizations with plasmids encoding
IFN-α or IL-12 along with antigen-encoding plasmids were able to
enhance CTL reactivity and shift the normally observed Th2 bias of
the immune response towards a Th1 phenotype (manuscript in
preparation). In keeping with these observations in rodents, we could
also consistently enhance the induction of immune responses with
plasmid DNA encoding melanoma antigens in an in vitro DNA vaccine
model by co-delivery of genes encoding the Th1-biasing cytokines
IFN-α or IL-12. Cultured autologous human PBMC-derived DC
were gene gun-transfected with antigen encoding cDNA for the
stimulation of primary antigen-specific CTL responses in vitro (Tu¨ting
et al, 1998).
Similarly, another strategy for the modulation of cell-mediated
immunity to plasmid encoded antigens is the adjuvant administration
of plasmids encoding costimulatory molecules like B7.1 and B7.2 in
order to provide additional signals required for full T cell activation.
Co-delivery of costimulatory molecule genes for B7.1 and B7.2 has
been shown to enhance the induction of cell-mediated immunity in
mice (Conry et al, 1996; Iwasaki et al, 1997b; Kim et al, 1997b; Corr
et al, 1997). In addition, co-delivery of cDNA encoding CD40 ligand
(CD154) can augment humoral and cellular immune responses to
antigens encoded by plasmid DNA expressing vectors (Mendoza et al,
1997). Presumably sustained CD40 ligand expression by transfected
cells augments CD40 mediated APC activation typically provided
through transient expression of CD40 ligand by T cells (Mendoza
et al, 1997).
DNA IMMUNIZATION: AN IMPORTANT TOOL FOR
DERMATOLOGISTS IN THE TWENTY-FIRST CENTURY
Plasmid DNA immunization represents an exciting new approach that
allows for the immediate application of advances in molecular biology
towards vaccine development. The co-delivery of plasmids encoding
immunomodulating cytokines or costimulatory molecules along with
plasmids encoding antigens allows control over the nature of the
immune response induced in vivo, which may be tailored towards
effector mechanisms that are best suited for a given therapeutic
application. Potential direct applications in the field of dermatology
include the prevention and treatment of infectious diseases such as
HIV, papilloma viruses, and recurrent herpes simplex, as well as
the immunotherapy of melanoma and cutaneous lymphoma. DNA
immunization may also prove useful for the immunomodulation of
allergic (Raz et al, 1996; Hsu et al, 1996) and autoimmune diseases
(Waisman et al, 1996). Whereas many aspects of the biology of
cutaneous DNA immunization remain unknown, the skin appears to
offer unique potential as a target for DNA-based immunization and
genetic engineering of the immune response.
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